Why Seres Therapeutics Stock Is Soaring Today

why seres therapeutics stock is soaring today

Sumary of Why Seres Therapeutics Stock Is Soaring Today:

  • The big gain came after the company announced that it has achieved its target enrollment of 300 participants in a phase 3 study evaluating SER-109 in treating recurrent C.
  • Seres inked a deal with Nestlé Health Science in July to co-market SER-109 in the U.S. and Canada, pending approvals.

Want to know more click here go to source.

From -

Generic selectors
Exact matches only
Search in title
Search in content

Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.